NR1H4 and metabolic dysfunction-associated steatohepatitis: Significant reduction in fibrosis among NASH/MASH patients with advanced fibrosis and compensated cirrhosis can occur in 26% with anti-fibrotic therapies such as FXR, PPAR, and anti-diabetic agents over 48 weeks of therapy [41].